ApprovedUpdate

YARTEMLEA® (narsoplimab-wuug)

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

OMEROmeros Corporation

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: YARTEMLEA® (narsoplimab-wuug)
Development stage: Approved
Event type: Update
Indication: Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

Research summary

What is being tracked?

This catalyst tracks a Approved update for YARTEMLEA® (narsoplimab-wuug) in Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- Q1 YARTEMLEA net sales were $9.9M; EMA decision expected Mid-2026. 06/26/26:- CHMP adopted negative opinion on EMA MAA; company to request re-examination and AHEG review.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source